Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The closing price of Corcept Therapeutics Inc (NASDAQ: CORT) was $71.53 for the day, down -3.29% from the previous closing price of $73.96. In other words, the price has decreased by -$3.29 from its previous closing price. On the day, 1.17 million shares were traded. CORT stock price reached its highest trading level at $76.84 during the session, while it also had its lowest trading level at $70.64.
Ratios:
Our analysis of CORT’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 22.02 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 41.81. For the most recent quarter (mrq), Quick Ratio is recorded 2.98 and its Current Ratio is at 3.06. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for the company, Truist on November 06, 2023, Upgraded its rating to Buy and sets its target price to $38 from $29 previously.
On April 11, 2023, SVB Securities started tracking the stock assigning a Market Perform rating and target price of $25.
On April 04, 2023, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $27.Piper Sandler initiated its Overweight rating on April 04, 2023, with a $27 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 10 ’25 when Swisher Daniel N JR bought 2,200 shares for $87.54 per share.
Guyer William sold 20,000 shares of CORT for $1,798,782 on Oct 07 ’25. The Chief Development Officer now owns 5,287 shares after completing the transaction at $89.94 per share. On Oct 07 ’25, another insider, Guyer William, who serves as the Officer of the company, bought 20,000 shares for $89.85 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CORT now has a Market Capitalization of 7793292800 and an Enterprise Value of 7201618944. As of this moment, Corcept’s Price-to-Earnings (P/E) ratio for their current fiscal year is 63.66, and their Forward P/E ratio for the next fiscal year is 36.26. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.99. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.53 while its Price-to-Book (P/B) ratio in mrq is 11.85. Its current Enterprise Value per Revenue stands at 10.057 whereas that against EBITDA is 70.177.
Stock Price History:
The Beta on a monthly basis for CORT is 0.48, which has changed by 0.52711356 over the last 52 weeks, in comparison to a change of 0.1443547 over the same period for the S&P500. Over the past 52 weeks, CORT has reached a high of $117.33, while it has fallen to a 52-week low of $42.01. The 50-Day Moving Average of the stock is -5.39%, while the 200-Day Moving Average is calculated to be 3.68%.
Shares Statistics:
CORT traded an average of 844.42K shares per day over the past three months and 982330 shares per day over the past ten days. A total of 105.29M shares are outstanding, with a floating share count of 93.32M. Insiders hold about 11.43% of the company’s shares, while institutions hold 75.36% stake in the company. Shares short for CORT as of 1759190400 were 10644876 with a Short Ratio of 12.61, compared to 1756425600 on 10881585. Therefore, it implies a Short% of Shares Outstanding of 10644876 and a Short% of Float of 13.65.
Earnings Estimates
Investors are keenly observing as 4.0 analysts analyze and rate. The current performance of Corcept Therapeutics Inc (CORT) in the stock market.The consensus estimate for the next quarter is $0.4, with high estimates of $0.53 and low estimates of $0.34.
Analysts are recommending an EPS of between $1.14 and $0.82 for the fiscal current year, implying an average EPS of $1.0. EPS for the following year is $1.97, with 4.0 analysts recommending between $3.19 and $0.77.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 4 analysts. It ranges from a high estimate of $240M to a low estimate of $189.1M. As of. The current estimate, Corcept Therapeutics Inc’s year-ago sales were $182.55MFor the next quarter, 4 analysts are estimating revenue of $282.58M. There is a high estimate of $287.8M for the next quarter, whereas the lowest estimate is $275.9M.
A total of 4 analysts have provided revenue estimates for CORT’s current fiscal year. The highest revenue estimate was $875M, while the lowest revenue estimate was $823.98M, resulting in an average revenue estimate of $852.72M. In the same quarter a year ago, actual revenue was $675.04MBased on 4 analysts’ estimates, the company’s revenue will be $1.15B in the next fiscal year. The high estimate is $1.39B and the low estimate is $1.01B.
